JRCT ID: jRCT1050230125
Registered date:09/11/2023
Multi-institutional observational study of dermatologic events sssociated with enfortumab vedotin
Basic Information
| Recruitment status | Recruiting |
|---|---|
| Health condition(s) or Problem(s) studied | Urothelila carcinoma |
| Date of first enrollment | 09/11/2023 |
| Target sample size | 300 |
| Countries of recruitment | |
| Study type | Observational |
| Intervention(s) |
Outcome(s)
| Primary Outcome | Details of dermatological evens after enfortumab vedotin administration (frequency, timing, location) |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | Not applicable |
|---|---|
| Age maximum | Not applicable |
| Gender | Both |
| Include criteria | Patients with unresectable or metastatic urothelial carcinoma who received enfortumab vedotin between January 1, 2020 and May 31, 2023 at the Department of Urology, Kyoto University Hospital and at participating institutions in the multicenter study. |
| Exclude criteria | Not available |
Related Information
| Primary Sponsor | Kita Yuki |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Astellas Pharma Inc. |
| Secondary ID(s) |
Contact
| Public contact | |
| Name | YUKI KITA |
| Address | Kyotoshi Sakyouku Syogoinkawaharacyo 54 Japan 606-8507 |
| Telephone | +81-75-751-3337 |
| kitayuki@kuhp.kyoto-u.ac.jp | |
| Affiliation | Kyoto University Hospital |
| Scientific contact | |
| Name | Yuki Kita |
| Address | Kyoto-shi Sakyo-ku Shogoinkawahara-cho 54 Kyoto Japan 606-8507 |
| Telephone | +81-75-751-3337 |
| kitayuki@kuhp.kyoto-u.ac.jp | |
| Affiliation | Kyoto University Hospital |